Glaukos Co. (NYSE:GKOS) Receives $87.30 Consensus Price Target from Brokerages

Glaukos Co. (NYSE:GKOSGet Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $87.30.

GKOS has been the subject of several research reports. StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Piper Sandler boosted their price objective on shares of Glaukos from $90.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, December 22nd. Truist Financial reissued a “buy” rating and set a $100.00 price objective on shares of Glaukos in a report on Friday, December 29th. JPMorgan Chase & Co. upgraded shares of Glaukos from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $66.00 to $91.00 in a research report on Thursday, December 21st. Finally, TheStreet lowered shares of Glaukos from a “c-” rating to a “d+” rating in a research report on Friday, November 24th.

Check Out Our Latest Stock Report on Glaukos

Glaukos Trading Up 2.4 %

Shares of NYSE GKOS opened at $93.31 on Friday. Glaukos has a 1 year low of $44.26 and a 1 year high of $94.77. The stock has a market cap of $4.55 billion, a P/E ratio of -34.69 and a beta of 1.11. The firm has a 50-day moving average of $80.70 and a 200 day moving average of $74.42. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.95 and a quick ratio of 5.36.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 9,476 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $94.12, for a total value of $891,881.12. Following the transaction, the chief operating officer now owns 119,802 shares of the company’s stock, valued at approximately $11,275,764.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, COO Joseph E. Gilliam sold 9,476 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $94.12, for a total value of $891,881.12. Following the transaction, the chief operating officer now owns 119,802 shares of the company’s stock, valued at approximately $11,275,764.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Alex R. Thurman sold 1,270 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $79.80, for a total transaction of $101,346.00. Following the completion of the transaction, the chief financial officer now directly owns 55,825 shares in the company, valued at approximately $4,454,835. The disclosure for this sale can be found here. In the last quarter, insiders sold 258,370 shares of company stock worth $21,543,878. 7.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in GKOS. National Bank of Canada FI purchased a new position in shares of Glaukos in the 4th quarter worth approximately $46,000. GAMMA Investing LLC acquired a new stake in Glaukos in the 4th quarter worth approximately $55,000. Silverarc Capital Management LLC acquired a new stake in Glaukos in the 2nd quarter worth approximately $71,000. Tower Research Capital LLC TRC boosted its stake in Glaukos by 257.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier’s stock worth $62,000 after purchasing an additional 892 shares in the last quarter. Finally, CWM LLC boosted its stake in Glaukos by 309.5% in the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,046 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

About Glaukos

(Get Free Report

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Stories

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.